JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$761M |
| 2 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$735M |
| 3 |
Zimmer Biomet
ZBH
|
+$542M |
| 4 |
Amazon
AMZN
|
+$439M |
| 5 |
iShares Core MSCI EAFE ETF
IEFA
|
+$438M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.01B |
| 2 |
Vanguard S&P 500 ETF
VOO
|
+$1.11B |
| 3 |
AABA
Altaba Inc
AABA
|
+$699M |
| 4 |
TJX Companies
TJX
|
+$682M |
| 5 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 22.01% |
| 2 | Financials | 14.82% |
| 3 | Technology | 12.49% |
| 4 | Healthcare | 9.61% |
| 5 | Consumer Discretionary | 8.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
EARN
2776
Ellington Residential Mortgage REIT
EARN
$151M
| $3.76M | ﹤0.01% |
312,357
-30,383
| -9% | -$404K |
2016 Q1
7 quarters
|
|
2777
La-Z-Boy
LZB
$1.2B
| $3.76M | ﹤0.01% |
120,557
-66,485
| -36% | -$1.92M |
2013 Q2
18 quarters
|
|
|
KDNY
2778
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $3.76M | ﹤0.01% |
100,292
+27,102
| +37% | +$1.18M |
2015 Q2
10 quarters
|
|
2779
CALL
Cemex
CX
$13.8B
| $3.75M | ﹤0.01% |
+500,000
| New | +$3.95M |
2017 Q4
0 quarters
|
|
|
ARC
2780
DELISTED
ARC Document Solutions, Inc.
ARC
| $3.74M | ﹤0.01% |
1,465,323
-57,599
| -4% | -$190K |
2013 Q2
18 quarters
|
|
2781
Imperial Oil
IMO
$60.8B
| $3.73M | ﹤0.01% |
119,749
+4,960
| +4% | +$154K |
2013 Q2
18 quarters
|
|
|
RDUS
2782
DELISTED
Radius Health, Inc.
RDUS
| $3.73M | ﹤0.01% |
117,503
+5,053
| +4% | +$159K |
2014 Q2
14 quarters
|
|
|
EVHC
2783
PUT
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $3.73M | ﹤0.01% |
+108,000
| New | +$3.78M |
2017 Q4
0 quarters
|
|
2784
CALL
United States Natural Gas Fund
UNG
$530M
| $3.73M | ﹤0.01% |
40,000
| – | – |
2017 Q3
1 quarter
|
|
2785
Cenovus Energy
CVE
$59.8B
| $3.73M | ﹤0.01% |
408,281
+10,710
| +3% | +$104K |
2013 Q2
18 quarters
|
|
2786
Abeona Therapeutics
ABEO
$288M
| $3.72M | ﹤0.01% |
+9,391
| New | +$3.88M |
2017 Q4
0 quarters
|
|
|
STB
2787
DELISTED
Student Transportation Inc
STB
| $3.71M | ﹤0.01% |
604,400
+227,600
| +60% | +$1.35M |
2017 Q2
2 quarters
|
|
2788
Vanguard FTSE All-World ex-US Small-Cap Index Fund
VSS
$11.7B
| $3.71M | ﹤0.01% |
31,118
+2,439
| +9% | +$284K |
2013 Q3
17 quarters
|
|
|
ITG
2789
DELISTED
Investment Technology Group Inc
ITG
| $3.71M | ﹤0.01% |
192,670
-13,036
| -6% | -$264K |
2013 Q2
18 quarters
|
|
2790
PUT
Teva Pharmaceutical Industries Limited
TEVA
$46.1B
| $3.69M | ﹤0.01% |
195,000
+125,000
| +179% | +$1.88M |
2016 Q4
4 quarters
|
|
|
BUFF
2791
DELISTED
Blue Buffalo Pet Products, Inc
BUFF
| $3.69M | ﹤0.01% |
112,519
+23,903
| +27% | +$708K |
2016 Q1
7 quarters
|
|
2792
Emergent Biosolutions
EBS
$325M
| $3.68M | ﹤0.01% |
79,155
+65,667
| +487% | +$2.76M |
2014 Q1
15 quarters
|
|
2793
PUT
Lazard
LAZ
$3.52B
| $3.67M | ﹤0.01% |
+70,000
| New | +$3.35M |
2017 Q4
0 quarters
|
|
2794
CALL
ConocoPhillips
COP
$152B
| $3.67M | ﹤0.01% |
+66,900
| New | +$3.44M |
2017 Q4
0 quarters
|
|
|
SINA
2795
DELISTED
Sina Corp
SINA
| $3.66M | ﹤0.01% |
36,520
-134,593
| -79% | -$14.4M |
2015 Q4
8 quarters
|
|
|
TYPE
2796
DELISTED
Monotype Imaging Holdings Inc.
TYPE
| $3.66M | ﹤0.01% |
152,014
+44,868
| +42% | +$1.05M |
2013 Q2
18 quarters
|
|
2797
CALL
Rambus
RMBS
$12.1B
| $3.66M | ﹤0.01% |
257,300
-175,000
| -40% | -$2.52M |
2017 Q3
1 quarter
|
|
2798
Resources Connection
RGP
$134M
| $3.66M | ﹤0.01% |
236,760
-7,434
| -3% | -$115K |
2013 Q2
18 quarters
|
|
|
GPMT
2799
Granite Point Mortgage Trust
GPMT
$36.7M
| $3.66M | ﹤0.01% |
+206,143
| New | +$3.75M |
2017 Q4
0 quarters
|
|
2800
CEMIG Preferred Shares
CIG
$6.15B
| $3.65M | ﹤0.01% |
3,478,679
-5,611,376
| -62% | -$6.38M |
2013 Q2
18 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2017 Portfolio in Review
As of Q4 2017, JP Morgan Chase held 5,783 positions worth $475B, up 4.7% from $453B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q4 2017 filing shows 812 new, 2,513 increased, 1,655 reduced and 342 closed positions. Its largest new stake was Delphi Technologies PLC Ordinary Shares: 2,961,446 shares worth $155M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $4.01B.
By sector, the portfolio is most concentrated in Miscellaneous at 22% of assets, down from 24% a quarter earlier, followed by Financials and Technology.
- JP Morgan Chase's largest Q4 2017 buy was Delphi Technologies PLC Ordinary Shares: 2,961,446 shares worth $155M.
- JP Morgan Chase added most to Johnson & Johnson in Q4 2017, an estimated $761M increase.
- JP Morgan Chase's biggest Q4 2017 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $4.01B.
- JP Morgan Chase fully exited Kite Pharma, Inc. in Q4 2017, selling an estimated $275M.
- JP Morgan Chase's ten largest holdings make up 18% of its $475B portfolio in Q4 2017.
- JP Morgan Chase opened 812 new positions and closed 342 in Q4 2017.
- JP Morgan Chase's portfolio value rose 4.7% quarter-over-quarter to $475B.
Based on JP Morgan Chase's 13F filing for Q4 2017, filed 13 Feb 2018.